A traditional medicine, respiratory detox shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the influenza A virus in vitro

Hetrick, Brian; Yu, Dongyang; Olanrewaju, Adeyemi A.; Chilin, Linda D.; He, Sijia; Dabbagh, Deemah; Alluhaibi, Ghaliah; Ma, Yuan-Chun; Hofmann, Lewis A.; Hakami, Ramin M.; Wu, Yuntao

doi:10.1186/s13578-021-00609-1

Cited by 10 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Natural products are essential to patient care because of their distinctive structural, chemical, and biological variety. They are a traditional source for contemporary pharmaceutical discovery and possible therapeutic leads [ 56 , 57 ]. Remdesivir, an antiviral medicine, has received significant recognition for its capacity to regulate viral infection and was approved by the FDA for treating COVID-19 patients suffering from pneumonia at the same time as an oxygen supply crisis [ 58 ].…”

Section: Novel Covid-19 Therapeutic Strategiesmentioning

confidence: 99%

Recent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOV_S1_CTD of the S Protein

Gupta

Singh

et al. 2023

Viruses

View full text Add to dashboard Cite

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the virus kept developing and mutating into different variants over time, which also gained increased transmissibility and spread in populations at a higher pace, culminating in successive waves of COVID-19 cases. The scientific community has developed vaccines and antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease. Realizing that growing SARS-CoV-2 variations significantly impact the efficacy of antiviral therapies and vaccines, we summarize the appearance and attributes of SARS-CoV-2 variants for future perspectives in drug design, providing up-to-date insights for developing therapeutic agents targeting the variants. The Omicron variant is among the most mutated form; its strong transmissibility and immune resistance capacity have prompted international worry. Most mutation sites currently being studied are in the BCOV_S1_CTD of the S protein. Despite this, several hurdles remain, such as developing vaccination and pharmacological treatment efficacies for emerging mutants of SARS-CoV-2 strains. In this review, we present an updated viewpoint on the current issues faced by the emergence of various SARS-CoV-2 variants. Furthermore, we discuss the clinical studies conducted to assist the development and dissemination of vaccines, small molecule therapeutics, and therapeutic antibodies having broad-spectrum action against SARS-CoV-2 strains.

show abstract

Section: Novel Covid-19 Therapeutic Strategiesmentioning

confidence: 99%

Recent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOV_S1_CTD of the S Protein

Gupta

Singh

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Recently, researchers' attention has been drawn to miRNA-based therapies, with some beginning precise in silico studies to link the SARS-CoV-2 genome to the human miRNome to better understand infectious miRNAs' contribution to SARS-CoV-2 infections (15). One study, drawing on computational studies, suggests that miR-27b plays a critical regulatory role in SARS-CoV-2 infection, showing an important correlation with ACE2.…”

Section: Host Proteinsmentioning

confidence: 99%

A Review on Herbal Secondary Metabolites Against COVID-19 Focusing on the Genetic Variants of SARS-CoV-2

Mohammadi

Yahyapour

Nasrollahian

et al. 2022

Jundishapur J Nat Pharm Prod

View full text Add to dashboard Cite

Context: An outbreak of the new coronavirus disease 2019 (COVID-19) was reported in Wuhan, China, in December 2019, subsequently affecting countries worldwide and causing a pandemic. Although several vaccines, such as mRNA vaccines, inactivated vaccines, and adenovirus vaccines, have been licensed in several countries, the danger of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants persists. To date, Alpha (B.1.1.7), Beta (B.1.351, B.1.351.2, B.1.351.3), Delta (B.1.617.2, AY.1, AY.2, AY. 3), Gamma (P.1, P.1.1, P.1.2), and Iota (B.1 .526) circulating in the United States, Kappa (B.1.617.1) in India, Lambda (C.37) in Peru and Mu (B.1.621) in Colombia are considered the variants of concern and interest. Evidence Acquisition: Data were collected through the end of August 2021 by searching PubMed, Scopus, and Google Scholar databases. There were findings from in silico, in vitro cell-based, and non-cell-based investigations. Results: The potential and safety profile of herbal medicines need clarification to scientifically support future recommendations regarding the benefits and risks of their use. Conclusions: Current research results on natural products against SARS-CoV-2 and variants are discussed, and their specific molecular targets and possible mechanisms of action are summarized.

show abstract

“…The COVID-19 pandemic, resulting from the infection of the SARS-CoV-2, has had a global impact, prompting extensive vaccination as a vital strategy to mitigate its effects. In order to control the pandemic, the scientific community has made significant progress in mitigating the threat of COVID-19 through the discovery and development of vaccines [ 1 ], small molecule agents [ 2 ], antibodies [ 3 ], natural products [ 4 ], and traditional medicines [ 5 ]. Clinical trials of COVID-19 vaccines have yielded compelling evidence supporting their overall safety and efficacy [ 6 , 7 , 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report

Lin

Hsu

et al. 2023

Vaccines

View full text Add to dashboard Cite

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening complication caused by platelet activation via platelet factor 4 (PF4) antibodies. We report a healthy 28-year-old man who developed hemoptysis, bilateral leg pain, and headaches three weeks after his third dose of the COVID-19 vaccine with the first BNT162b2 (from Pfizer-BioNTech) injection. He had previously had the first and second doses with ChAdOx1 nCov-19 without any discomfort. Serial investigations demonstrated pulmonary embolisms, cerebral sinus, and deep iliac venous thrombosis. Positive PF4 antibody assay (ELISA) confirmed the diagnosis of VITT. He had a prompt response to intravenous immunoglobulins (IVIGs) at a total dose of 2 g/kg and his symptoms are now in remission with anticoagulant. Although the definite mechanism is unknown, the VITT was most likely triggered by his COVID-19 vaccine. We report this case of VITT following BNT162b2, a mRNA-based vaccine, and suggest that VITT could still happen without the adenoviral vector vaccines.

show abstract

A traditional medicine, respiratory detox shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the influenza A virus in vitro

Cited by 10 publications

References 36 publications

Recent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOV_S1_CTD of the S Protein

Recent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOV_S1_CTD of the S Protein

A Review on Herbal Secondary Metabolites Against COVID-19 Focusing on the Genetic Variants of SARS-CoV-2

Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report

Contact Info

Product

Resources

About